Neuromyopathies in the Critically Ill

  • Francis C. Cordova
  • Maria Roselyn Lim
  • Gerard J. Criner

Abstract

Neuromuscular disorders are increasingly recognized as a significant contributor of morbidity and mortality in the intensive care unit (ICU). This recognition is largely brought about by the increased awareness of acquired neuromuscular dysfunction following acute life-threatening illness. Indeed, the development of acquired neuromyopathy during the course of treatment of life-threatening illness such as acute myopathy and critical illness polyneuropathy has replaced traditional causes of neuromyopathy (Guillain—Barré syndrome, myasthenia gravis) as the most common origin of muscle weakness in the ICU.

Keywords

Forced Vital Capacity Respiratory Muscle Amyotrophic Lateral Sclerosis Patient Neuromuscular Disease Noninvasive Positive Pressure Ventilation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Suggested Reading

  1. Braun NMT, Arora NS, Rochester DE Respiratory muscle and pulmonary function in polymyosities and other proximal myopathies. Thorax 1983; 38: 616–623.PubMedCrossRefGoogle Scholar
  2. Ellis ER, Bye PTP, Bruderer JW, Sullivan CE. Treatment of respiratory failure during sleep in patients with neuromuscular disease. Am Rev Respir Dis 1987; 135: 148–152.PubMedGoogle Scholar
  3. Gibson GJ. Diaphragmatic paresis: pathophysiology, clinical features, and investigation. Thorax 1989; 44: 960–970.PubMedCrossRefGoogle Scholar
  4. Kelly BJ, Luce JM. The diagnosis and management of neuromuscular disease causing respiratory failure. Chest 1991; 99: 1485–1494.PubMedCrossRefGoogle Scholar
  5. McCool FD, Mayewski RF, Shayne DS, Gibson CJ, Griggs RC, Hyde RW. Intermittent positive pressure breathing in patients with respiratory muscle weakness. Chest 1986; 90: 546–551.PubMedCrossRefGoogle Scholar
  6. McKhan GM, Griffin JW, Cornblath DR, Mellits ED, Fisher RS, Quaskey SA, et al. Plasmapheresis and Guillain-Barré syndrome: analysis of prognostic factors and the effects of plasmapheresis. Ann Neurol 1988; 23: 347–353.CrossRefGoogle Scholar
  7. Plasma Exchange/Sandoglobulin Guillain-Barré Trial Group. Randomized trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Lancet 1997; 349: 225–230.Google Scholar
  8. Rochester DF, Esau SA. Assessment of ventilatory function in patients with neuromuscular disease. Clin Chest Med 1994; 15 (4): 751–763.PubMedGoogle Scholar
  9. RopperAH. The Guillain-Barre syndrome. N Engl J Med 1992; 326 (6): 1130–1136.Google Scholar
  10. Unterborn JN, Hill NS. Options for mechanical ventilation in neuromuscular diseases. Clin Chest Med 1994; 15 (4): 765–781.PubMedGoogle Scholar
  11. van der Meche FGA, Schmitz PIM, the Dutch Guillain-Barré Study Group. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. N Engl J Med 1992; 326: 1123–1129.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2002

Authors and Affiliations

  • Francis C. Cordova
  • Maria Roselyn Lim
  • Gerard J. Criner

There are no affiliations available

Personalised recommendations